Abstract: The present invention relates to progesterone receptor antagonists of general formula I: in which R1 can be a hydrogen atom and R2 a hydroxyl group or R1 and R2 together can be an oxo group.
Type:
Grant
Filed:
November 15, 2007
Date of Patent:
November 8, 2011
Assignee:
Bayer Schering Pharma AG
Inventors:
Ulrike Fuhrmann, Anja Schmidt, Arwed Cleve, Orlin Petrov, Gunnar Garke, Stefan Pruehs, Margarete Brudny-Kloeppel, Antje Rottmann, Rainer Hasselmann, Marcus Schultze-Mosgau, Carsten Moeller
Abstract: The invention relates to novel 2-heteroaryl carboxamides and to the use thereof for producing medicaments for the treatment and/or prophylaxis of diseases and for improving perception, concentration, learning and/or memory.
Type:
Application
Filed:
July 11, 2011
Publication date:
October 27, 2011
Applicant:
Bayer Schering Pharma AG
Inventors:
Joachim Luithle, Frank-Gerhard Böss, Christina Erb, Frank-Thorsten Hafner, Katrin Schnizler, Timo Flessner, Marja van Kampen, Franz-Josef van der Staay
Abstract: The present invention relates to the generation of replication-competent viruses having therapeutic utility. The replication-competent viruses of the invention can express proteins useful in the treatment of disease.
Type:
Application
Filed:
June 22, 2009
Publication date:
September 8, 2011
Applicant:
BAYER SCHERING PHARMA AG
Inventors:
Terry HERMISTON, Fang JIN, Peter KRETSCHMER
Abstract: Compounds of the following formula (I), for example: wherein R1, R2, R3, and R4 are described herein, are useful as inhibitors of plasma carboxypeptidase B. Pharmaceutical compositions containing these compounds, methods of using these compounds as antithrombotic agents and processes for synthesizing these compounds are also described herein.
Type:
Grant
Filed:
December 11, 2008
Date of Patent:
August 30, 2011
Assignee:
Bayer Schering Pharma AG
Inventors:
Brad O. Buckman, Kumar Emayan, Imadul Islam, Karen May, Judi Bryant, Raju Mohan, Christopher West, Shendong Yuan
Abstract: The present invention relates to a quinoline or quinazoline derivative having the general formula (A): in which R3, R4, W, Y and Q are indicated in the description and the claims, the use of the compounds of the general formula (A) for the treatment of various disorders, and the preparation of compounds of the general formula (A).
Type:
Grant
Filed:
May 23, 2008
Date of Patent:
August 23, 2011
Assignee:
Bayer Schering Pharma AG
Inventors:
Knut Eis, Olaf Prien, Ulrich Lücking, Judith Günther, Dieter Zopf, Dirk Brohm, Verena Vöhringer, Elisabeth Woltering, Hartmut Beck, Mario Lobell, Volkhart Min-Jian Li, Susanne Greschat
Abstract: The invention relates to substituted sulphoximines according to the general formula (I): in which A, E, G, X, R1, R2, R3, R4, R5, R6, R7, R8, m, p, q, are given in the claims, and salts thereof, to pharmaceutical compositions comprising said substituted sulphoximines, to methods of preparing said substituted sulphoximines as well as the use thereof for manufacturing a pharmaceutical composition for the treatment of diseases of dysregulated vascular growth or of diseases which are accompanied with dysregulated vascular growth, wherein the compounds effectively interfere with Tie2 signalling.
Type:
Grant
Filed:
July 11, 2007
Date of Patent:
August 23, 2011
Assignee:
Bayer Schering Pharma AG
Inventors:
Ingo Hartung, Georg Kettschau, Hans Briem, Karl-Heinz Thierauch, Ulrich Luecking, Ulf Boemer, Martin Krueger
Abstract: To monitor the intake of medicaments present in wafer form, a device is made available which is suitable for storage and provision of such forms of administration. This device comprises medicament pouches, which are arranged as a stack of pouches and contain medicament wafers, and it has the following features: a) the device has a support 9 which extends parallel to an edge of the medicament pouches 1 and on which date indicators are arranged, b) a marking 20 is arranged on each of the medicament pouches 1 in such a way that markings 20 arranged on successive medicament pouches 1 in the stack of pouches are each in alignment with successive date indicators. This ensures monitoring of the intake of the wafers.
Abstract: This invention relates to compounds of general formula I in which R1 and R2 are described in this application, the use of the compounds of general formula I as inhibitors of protein tyrosine kinases for treatment of various diseases as well as the compounds of general formulas II and III as intermediate compounds for the production of compounds of general formula I, wherein X, R1a and R2a have the meaning that is described in general formulas II and III.
Type:
Grant
Filed:
December 14, 2005
Date of Patent:
July 12, 2011
Assignee:
Bayer Schering Pharma AG
Inventors:
Wolfgang Schwede, Hermann Kuenzer, Antonius Ter Laak, Benjamin Bader, Roman Hillig, Ursula Moenning, Arndt Schmitz, Dieter Zopf
Abstract: The crystalline Polymorph B of N-(2-aminophenyl)-4-[N-(pyridine-3-yl)methoxy-carbonyaminomethyl]benzamide (MS-275) of formula I is described, as well as the process for the production of said compound, and its use as a medicament for the treatment of selected diseases.
Type:
Grant
Filed:
August 28, 2009
Date of Patent:
July 5, 2011
Assignee:
Bayer Schering Pharma AG
Inventors:
Matthias Schneider, Michael Gottfried, Jens Geisler, Gabriele Winter
Abstract: The present invention relates to a novel cocrystal compound of 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide (rivaroxaban) and malonic acid, to processes for its preparation, to medicaments comprising this compound and to their use for controlling diseases.
Type:
Application
Filed:
June 3, 2009
Publication date:
June 23, 2011
Applicant:
Bayer Schering Pharma AG
Inventors:
Alfons Grunenberg, Karsten Fähnrich, Olaf Queckenberg, Christiane Reute, Birgit Keil, Karen Sue Gushurst, Ezra John Still
Abstract: The present invention relates to progesterone receptor antagonists of general formula I: in which R1 can be a hydrogen atom and R2 a hydroxyl group or R1 and R2 together can be an oxo group.
Type:
Grant
Filed:
November 15, 2007
Date of Patent:
May 31, 2011
Assignee:
Bayer Schering Pharma AG
Inventors:
Ulrike Fuhrmann, Anja Schmidt, Arwed Cleve, Orlin Petrov, Gunnar Garke, Stefan Pruehs, Margarete Brudny-Kloeppel, Antje Rottmann, Rainer Hasselmann, Marcus Schultze-Mosgau, Carsten Moeller
Abstract: Various methods for optimizing coating of medical devices, such as balloon catheters are disclosed. One method configures catheter balloon folds based on balloon diameter and volume. Other methods include using a specifically-sized protective sheath, using a vacuum, using pressure, pulling the balloon through a coating solution, using at least one spacer or a wick between at least one fold for metering a therapeutic coating into the folds of the balloon, placing an intermediate layer between the balloon and the therapeutic coating, placing a soluble film having a therapeutic agent around the catheter balloon or inside the folds, and any combination thereof. Balloon catheters and catheter balloons having a specific folding configuration, a specifically-sized protective sheath, an intermediate layer, or a soluble film are also disclosed.
Type:
Application
Filed:
May 1, 2009
Publication date:
May 5, 2011
Applicant:
Bayer Schering Pharma AG
Inventors:
Benjamin T. Ewing, Gregory G. Brucker, Scott A. Bednar, John R. Periard, Ashok A. Sharma, Steven D. Savage, Arthur E. Uber, Brian P. Dickerson
Abstract: The present invention relates to new optically active heteroaromatic ?-hydroxy esters useful in the synthesis of epothilone derivatives, to certain compounds used to produce these intermediates, as well as to processes for their production.
Type:
Grant
Filed:
December 18, 2008
Date of Patent:
May 3, 2011
Assignee:
Bayer Schering Pharma AG
Inventors:
Johannes Platzek, Ludwig Zorn, Bernd Buchmann, Werner Skuballa, Orlin Petrov
Abstract: The present invention is directed to a polynucleotide sequence of a novel acylglycerol acyltransferase-like protein MGAT-X1. The invention also provides the human MGAT-X1 associated with the dermatological diseases, urological diseases, muscle-skeleton disorders, hematological diseases, cancer, reproduction disorders, neurological diseases, metabolic diseases, cardiovascular diseases or gastroenterological diseases. The invention also provides assays for the identification of compounds useful for the modulation of dermatological diseases, urological diseases, muscle-skeleton disorders, hematological diseases, cancer, reproduction disorders, neurological diseases, metabolic diseases, cardiovascular diseases or gastroenterological diseases for treating of such diseases associated with expression of the MGAT-X1. The invention also features compounds which bind to and/or activate or inhibit the activity of MGAT-X1 as well as pharmaceutical compositions comprising such compounds.
Type:
Application
Filed:
August 31, 2010
Publication date:
April 14, 2011
Applicant:
BAYER SCHERING PHARMA AG
Inventors:
Stefan Golz, Ulf Brüggemeier, Bernhard Weingärtner, Andreas Geerts
Abstract: The present invention relates to crystalline forms of 11?-(4-acetylphenyl)-20,20,21,21,21-pentafluoro-17-hydroxy-19-nor-17?-pregna-4,9-dien-3-one. The invention relates in particular to two crystalline ansolvate/anhydrate forms of this compound, polymorphs I and II. However, the present invention also relates to crystalline solvates, for example methanol and ethanol solvates of 11?-(4-acetylphenyl)-20,20,21,21,21-pentafluoro-17-hydroxy-19-nor-17?-pregna-4,9-dien-3-one as precursors for preparing these two polymorphs I and II. Processes for preparing polymorph I by displacement crystallization or by trituration are described. Selection of the last solvent before formation of the ansolvate can be based on the differences in the purification behaviour of the individual solvates of 11?-(4-acetylphenyl)-20,20,21,21,21-pentafluoro-17-hydroxy-19-nor-17?-pregna-4,9-dien-3-one. Polymorph I according to the invention is particularly suitable for the manufacture of medicinal products.
Type:
Grant
Filed:
June 1, 2007
Date of Patent:
March 22, 2011
Assignee:
Bayer Schering Pharma AG
Inventors:
Wolfgang Beckmann, Gabriele Winter, Edda Kraemer, Thomas Ginko, Evelin Amoulong, Arwed Cleve
Abstract: The invention relates to novel nicotinamide pyridinureas as VEGF receptor kinase inhibitors, their production and use as pharmaceutical agents for preventing or treating diseases that are triggered by persistent angiogenesis.
Type:
Grant
Filed:
November 1, 2005
Date of Patent:
March 15, 2011
Assignee:
Bayer Schering Pharma AG
Inventors:
Rolf Bohlmann, Martin Haberey, Andreas Huth, Stuart Ince, Martin Krueger, Karl-Heinz Thierauch, Holger Hess-Stumpp